{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T16:47:15Z","timestamp":1789922835350,"version":"4.0.1"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neural Regen Res"],"published-print":{"date-parts":[[2015]]},"DOI":"10.4103\/1673-5374.153686","type":"journal-article","created":{"date-parts":[[2015,3,20]],"date-time":"2015-03-20T13:04:48Z","timestamp":1426856688000},"page":"391","source":"Crossref","is-referenced-by-count":29,"title":["A new look at auranofin, dextromethorphan and rosiglitazone for reduction of glia-mediated inflammation in neurodegenerative diseases"],"prefix":"10.4103","volume":"10","author":[{"given":"Andis","family":"Klegeris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JocelynM","family":"Madeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"StephanieM","family":"Schindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/1673-5374.153686-1","doi-asserted-by":"crossref","unstructured":"Bouhlel MA, Derudas B, Rigamonti E, Dievart R, Brozek J, Haulon S, Zawadzki C, Jude B, Torpier G, Marx N, Staels B, Chinetti-Gbaguidi G (2007) PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab 6:137-143.","DOI":"10.1016\/j.cmet.2007.06.010"},{"key":"key-10.4103\/1673-5374.153686-2","doi-asserted-by":"crossref","unstructured":"Chechneva OV, Mayrhofer F, Daugherty DJ, Pleasure DE, Hong JS, Deng W (2011) Low dose dextromethorphan attenuates moderate experimental autoimmune encephalomyelitis by inhibiting NOX2 and reducing peripheral immune cells infiltration in the spinal cord. Neurobiol Dis 44:63-72.","DOI":"10.1016\/j.nbd.2011.06.004"},{"key":"key-10.4103\/1673-5374.153686-3","doi-asserted-by":"crossref","unstructured":"Cuadrado A, Rojo AI (2008) Heme oxygenase-1 as a therapeutic target in neurodegenerative diseases and brain infections. Curr Pharm Des 14:429-442.","DOI":"10.2174\/138161208783597407"},{"key":"key-10.4103\/1673-5374.153686-4","doi-asserted-by":"crossref","unstructured":"Dinarello CA (2010) Anti-inflammatory agents: Present and future. Cell 140:935-950.","DOI":"10.1016\/j.cell.2010.02.043"},{"key":"key-10.4103\/1673-5374.153686-5","doi-asserted-by":"crossref","unstructured":"Gold M, Alderton C, Zvartau-Hind M, Egginton S, Saunders AM, Irizarry M, Craft S, Landreth G, Linnamagi U, Sawchak S (2010) Rosiglitazone monotherapy in mild-to-moderate Alzheimer\u2032s disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord 30:131-146.","DOI":"10.1159\/000318845"},{"key":"key-10.4103\/1673-5374.153686-6","doi-asserted-by":"crossref","unstructured":"Gonzalez H, Elgueta D, Montoya A, Pacheco R (2014) Neuroimmune regulation of microglial activity involved in neuroinflammation and neurodegenerative diseases. J Neuroimmunol 274:1-13.","DOI":"10.1016\/j.jneuroim.2014.07.012"},{"key":"key-10.4103\/1673-5374.153686-7","doi-asserted-by":"crossref","unstructured":"Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI (2002) Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106:679-684.","DOI":"10.1161\/01.CIR.0000025403.20953.23"},{"key":"key-10.4103\/1673-5374.153686-8","doi-asserted-by":"crossref","unstructured":"Hostenbach S, Cambron M, D\u2032Haeseleer M, Kooijman R, De Keyser J (2014) Astrocyte loss and astrogliosis in neuroinflammatory disorders. Neurosci Lett 565:39-41.","DOI":"10.1016\/j.neulet.2013.10.012"},{"key":"key-10.4103\/1673-5374.153686-9","doi-asserted-by":"crossref","unstructured":"Hyong A, Jadhav V, Lee S, Tong W, Rowe J, Zhang JH, Tang J (2008) Rosiglitazone, a PPAR gamma agonist, attenuates inflammation after surgical brain injury in rodents. Brain Res 1215:218-224.","DOI":"10.1016\/j.brainres.2008.04.025"},{"key":"key-10.4103\/1673-5374.153686-10","doi-asserted-by":"crossref","unstructured":"Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Bjornsson S, Huttenlocber J, Levey AI, Lah JJ, Rujescu D, Hampel H, Giegling I, Andreassen OA, Engedasl K, Ulstein I, Djurovic S, Ibrahim-Verbaas C, Hofman A, Ikram MA, van Duijn CM, et al. (2013) Variant of TREM2 associated with the risk of Alzheimer\u2032s disease. N Engl J Med 368:107-116.","DOI":"10.1056\/NEJMoa1211103"},{"key":"key-10.4103\/1673-5374.153686-11","doi-asserted-by":"crossref","unstructured":"Kean WF (1990) Intramuscular versus oral gold therapy. Baillieres Clin Rheumatol 4:219-246.","DOI":"10.1016\/S0950-3579(05)80019-6"},{"key":"key-10.4103\/1673-5374.153686-12","doi-asserted-by":"crossref","unstructured":"Keller M, Griesmaier E, Auer M, Schlager G, Urbanek M, Simbruner G, Gressens P, Sarkozy G (2008) Dextromethorphan is protective against sensitized N-methyl-D-aspartate receptor-mediated excitotoxic brain damage in the developing mouse brain. Eur J Neurosci 27:874-883.","DOI":"10.1111\/j.1460-9568.2008.06062.x"},{"key":"key-10.4103\/1673-5374.153686-13","doi-asserted-by":"crossref","unstructured":"Klegeris A, McGeer EG, McGeer PL (2007) Therapeutic approaches to inflammation in neurodegenerative disease. Curr Opin Neurol 20:351-357.","DOI":"10.1097\/WCO.0b013e3280adc943"},{"key":"key-10.4103\/1673-5374.153686-14","doi-asserted-by":"crossref","unstructured":"Lee M, McGeer E, Kodela R, Kashfi K, McGeer PL (2013) NOSH- aspirin (NBS-1120), a novel nitric oxide and hydrogen sulfide releasing hybrid, attenuates neuroinflammation induced by microglial and astrocytic activation: a new candidate for treatment of neurodegenerative disorders. Glia 61:1724-1734.","DOI":"10.1002\/glia.22553"},{"key":"key-10.4103\/1673-5374.153686-15","doi-asserted-by":"crossref","unstructured":"Liu Y, Qin L, Li G, Zhang W, An L, Liu B, Hong JS (2003) Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. J Pharmacol Exp Ther 305:212-218.","DOI":"10.1124\/jpet.102.043166"},{"key":"key-10.4103\/1673-5374.153686-16","doi-asserted-by":"crossref","unstructured":"Lucas SM, Rothwell NJ, Gibson RM (2006) The role of inflammation in CNS injury and disease. Br J Pharmacol 147 Suppl 1:S232-240.","DOI":"10.1038\/sj.bjp.0706400"},{"key":"key-10.4103\/1673-5374.153686-17","doi-asserted-by":"crossref","unstructured":"Luna-Medina R, Cortes-Canteli M, Alonso M, Santos A, Martinez A, Perez-Castillo A (2005) Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator-activated receptor gamma activation. J Biol Chem 280:21453-21462.","DOI":"10.1074\/jbc.M414390200"},{"key":"key-10.4103\/1673-5374.153686-18","doi-asserted-by":"crossref","unstructured":"Luo Y, Yin W, Signore AP, Zhang F, Hong Z, Wang S, Graham SH, Chen J (2006) Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. J Neurochem 97:435-448.","DOI":"10.1111\/j.1471-4159.2006.03758.x"},{"key":"key-10.4103\/1673-5374.153686-19","doi-asserted-by":"crossref","unstructured":"Madeira JM, Gibson DL, Kean WF, Klegeris A (2012) The biological activity of auranofin: implications for novel treatment of diseases. Inflammopharmacology 20:297-306.","DOI":"10.1007\/s10787-012-0149-1"},{"key":"key-10.4103\/1673-5374.153686-20","doi-asserted-by":"crossref","unstructured":"Madeira JM, Bajwa E, Stuart MJ, Hashioka S, Klegeris A (2014) Gold drug auranofin could reduce neuroinflammation by inhibiting microglia cytotoxic secretions and primed respiratory burst. J Neuroimmunol 276:71-79.","DOI":"10.1016\/j.jneuroim.2014.08.615"},{"key":"key-10.4103\/1673-5374.153686-21","doi-asserted-by":"crossref","unstructured":"Madeira JM, Renschler CJ, Mueller B, Hashioka S, Gibson DL, Klegeris A (2013) Novel protective properties of auranofin: inhibition of human astrocyte cytotoxic secretions and direct neuroprotection. Life Sci 92:1072-1080.","DOI":"10.1016\/j.lfs.2013.04.005"},{"key":"key-10.4103\/1673-5374.153686-22","doi-asserted-by":"crossref","unstructured":"Misra S, Medhi B (2013) Drug development status for Alzheimer\u2032s disease: present scenario. Neurol Sci 34:831-839.","DOI":"10.1007\/s10072-013-1316-x"},{"key":"key-10.4103\/1673-5374.153686-23","doi-asserted-by":"crossref","unstructured":"Tansey MG, Goldberg MS (2010) Neuroinflammation in Parkinson\u2032s disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 37:510-518.","DOI":"10.1016\/j.nbd.2009.11.004"},{"key":"key-10.4103\/1673-5374.153686-24","doi-asserted-by":"crossref","unstructured":"Tortella FC, Pellicano M, Bowery NG (1989) Dextromethorphan and neuromodulation: old drug coughs up new activities. Trends Pharmacol Sci 10:501-507.","DOI":"10.1016\/0165-6147(89)90050-3"},{"key":"key-10.4103\/1673-5374.153686-25","doi-asserted-by":"crossref","unstructured":"Yi JH, Park SW, Brooks N, Lang BT, Vemuganti R (2008) PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms. Brain Res 1244:164-172.","DOI":"10.1016\/j.brainres.2008.09.074"}],"container-title":["Neural Regeneration Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:27:01Z","timestamp":1786649221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/1673-5374.153686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015]]}},"alternative-id":["153686"],"URL":"https:\/\/doi.org\/10.4103\/1673-5374.153686","relation":{},"ISSN":["1673-5374"],"issn-type":[{"value":"1673-5374","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]}}}